Artemisinins ameliorate polycystic ovarian syndrome by mediating LONP1-CYP11A1 interaction.
Liu Y, Jiang JJ, Du SY, Mu LS, Fan JJ, Hu JC, Ye Y, Ding M, Zhou WY, Yu QH, Xia YF, Xu HY, Shi YJ, Qian SW, Tang Y, Li W, Dang YJ, Dong X, Li XY, Xu CJ, Tang QQ.
Science. 2024 Jun 14;384(6701):eadk5382. doi: 10.1126/science.adk5382. Epub 2024 Jun 14.
PMID:38870290
Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome: a comprehensive update.
Herlin MK, Petersen MB, Brännström M.
Orphanet J Rare Dis. 2020 Aug 20;15(1):214. doi: 10.1186/s13023-020-01491-9.
PMID:32819397
Physiopathology of polycystic ovary syndrome in endocrinology, metabolism and inflammation.
Su P, Chen C, Sun Y.
J Ovarian Res. 2025 Feb 20;18(1):34. doi: 10.1186/s13048-025-01621-6.
PMID:39980043
Female pseudohermaphroditism.
IBBERTSON HK, FRASER R.
Proc R Soc Med. 1958 Sep;51(9):723-4.
PMID:13591289
Polycystic Ovary Syndrome in Adolescents.
Saleh FL, Starkman H, Furness A, Pfeifer SM, Kives S.
Androgens drive SLC1A5-dependent metabolic reprogramming in polycystic ovary syndrome.
Wang Y, Wu J, Zhang G, Shi Y, Meng Y, Lv P, Huang W, Su Y, Zhou Z, Wang B, Chen X, Zhou C, Pan J, Jin L, Wang X, Wu Y, Sheng J, Liu X, Zhang Y, Ding G, Yu C, Huang H.
Nat Commun. 2025 Aug 15;16(1):7611. doi: 10.1038/s41467-025-62951-z.
PMID:40817119
Genetics of Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome: advancements and implications.
Herlin MK.
Front Endocrinol (Lausanne). 2024 Apr 18;15:1368990. doi: 10.3389/fendo.2024.1368990. eCollection 2024.